Close Menu

NEW YORK (GenomeWeb) — The Open Medicine Institute said last week that it will use Affymetrix expression microarrays to develop tests to diagnose and aid in the treatment of myalgic encephalomyelitis and chronic fatigue syndrome.

In addition, Mountain View, Calif.-based OMI, which aims to improve healthcare by using new approaches and technologies, said that it has become an Affymetrix certified service provider and will use the platform to develop diagnostics for other diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.